La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
COMPASS Pathways Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Kabir Nath
Amministratore delegato
US$2.8m
Compenso totale
| Percentuale dello stipendio del CEO | 21.0% |
| Mandato del CEO | 2yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | 2yrs |
| Durata media del Consiglio di amministrazione | 4.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06
Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18COMPASS Pathways: Risky But Can Pay Back Generously
Dec 14Compass Pathways: An Overvalued Psychedelic Company With A Single Mediocre Drug
Nov 23COMPASS Pathways ADS reports Q3 results
Nov 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$139m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$3m | US$595k | -US$118m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$102m |
| Mar 31 2023 | n/a | n/a | -US$95m |
| Dec 31 2022 | US$8m | US$243k | -US$92m |
Compensazione vs Mercato: La retribuzione totale di Kabir ($USD 2.82M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.44M ).
Compensazione vs guadagni: La retribuzione di Kabir è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Kabir Nath (60 yo)
2yrs
Mandato
US$2,824,758
Compensazione
Mr. Kabir Kumar Nath M. A., M. B.A., is Chief Executive Officer and Director of COMPASS Pathways plc from August 1, 2022. He serves as President & CEO at Otsuka America Pharmaceutical, Inc. He served as Pr...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$2.82m | 0.037% $ 177.2k | |
| General Counsel & Chief Legal Officer | 2.5yrs | US$1.32m | 0.0059% $ 28.5k | |
| Chief Medical Officer | 3.1yrs | US$1.20m | 0.0029% $ 14.1k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Technology Officer | 2.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Communications Officer | 1.8yrs | Nessun dato | Nessun dato | |
| Chief People Officer | no data | Nessun dato | Nessun dato | |
| Senior Advisor | 2.6yrs | Nessun dato | Nessun dato | |
| Advisor | no data | Nessun dato | Nessun dato | |
| Chief Research & Development Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | Nessun dato | Nessun dato |
2.0yrs
Durata media
51yo
Età media
Gestione esperta: Il team dirigenziale di CMPS è considerato esperto (durata media dell'incarico 2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$2.82m | 0.037% $ 177.2k | |
| Member of Scientific Advisory Network | no data | Nessun dato | Nessun dato | |
| Independent Non Executive Director | 3.9yrs | US$209.48k | 0% $ 0 | |
| Independent Chairman | 6.3yrs | US$215.57k | 0.025% $ 122.6k | |
| Independent Director | less than a year | US$363.71k | 0% $ 0 | |
| Independent Non Executive Director | 4.3yrs | US$210.84k | 0% $ 0 | |
| Independent Non-Executive Director | 3.4yrs | US$200.86k | 0% $ 0 | |
| Independent Non-Executive Director | 6.3yrs | US$199.82k | 0.13% $ 627.8k | |
| Independent Non-Executive Director | 6.3yrs | US$214.78k | 0.051% $ 245.9k | |
| Member of Scientific Advisory Network | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Network | no data | Nessun dato | Nessun dato | |
| Special Advisor of Patient Experience | no data | Nessun dato | Nessun dato |
4.1yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CMPS sono considerati esperti (durata media dell'incarico 4.1 anni).